• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bull Horn Holdings Corp. (Amendment)

    5/10/22 4:16:36 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BHSE alert in real time by email
    SC 13G/A 1 karpus-sch13g_18608.htm KARPUS INVESTMENT MGT / BULL HORN HOLDINGS - SCHEDULE 13G/A(#1)

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

      (Amendment No. 1) *

     

     

    Bull Horn Holdings Corp.

    (Name of Issuer)

       

    Common

     

    (Title of Class of Securities)

      

    G1686P106

     

    (CUSIP Number)

      

    April 30, 2022

     

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☐   Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

    CUSIP No.  G1686P106

    13G Page 2 of 5 Pages    

    1.  

    NAME OF REPORTING PERSON(S)

     

    Karpus Investment Management

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☒

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New York 

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5.

     

    SOLE VOTING POWER

     

    33,931 Shares

     

      6.  

    SHARED VOTING POWER

     

    0 Shares

     

      7.  

    SOLE DISPOSITIVE POWER

     

    33,931 Shares

     

      8.  

    SHARED DISPOSITIVE POWER

     

    0 Shares

     

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    33,931 Shares

     

       
    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    0.36%

     

       

     12.

     

    TYPE OF REPORTING PERSON

       

    IA

     

       

     

     
     

    CUSIP No.  G1686P106

    13G Page 3 of 5 Pages    

     

     

    Item 1(a). Name of Issuer:

     

    Bull Horn Holdings Corp.

     

     

     

    Item 1(b). Address of Issuer's Principal Executive Offices:

     

    801 South Pointe Drive, Suite TH-1, Miami Beach, FL 33139

     

     

     

    Item 2(a). Name of Person Filing:

     

    This statement is being filed by Karpus Management, Inc., d/b/a Karpus Investment Management (“Karpus” or the “Reporting Person”). Karpus is a registered investment adviser under Section 203 of the Investment Advisers Act of 1940. Karpus is controlled by City of London Investment Group plc (“CLIG”), which is listed on the London Stock Exchange. However, in accordance with SEC Release No. 34-39538 (January 12, 1998), effective informational barriers have been established between Karpus and CLIG such that voting and investment power over the subject securities is exercised by Karpus independently of CLIG, and, accordingly, attribution of beneficial ownership is not required between Karpus and CLIG.

     

    The Shares to which this Schedule 13G relates are owned directly by the accounts managed by Karpus.

     

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    183 Sully's Trail, Pittsford, New York 14534.

     

     

     

    Item 2(c). Citizenship:

     

    The members of the Karpus Management Committee are US citizens. Karpus is a New York corporation.

     

     

     

    Item 2(d). Title of Class of Securities.

     

    Common

     

     

     

    Item 2(e). CUSIP Number.

     

    G1686P106

     

     

      

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)  ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

    (b)  ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
    (c)  ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
    (d)  ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
    (e)  ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f)  ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g)  ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
    (h)  ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)  ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ☐  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
    (k)  ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     
     

    CUSIP No.   G1686P106

    13G Page 4 of 5 Pages    

     

     

    Item 4. Ownership:

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)       Amount beneficially owned:   33,931

    (b)       Percent of Class:    0.36%

    (c)       Number of shares as to which such person has:

    (i)     Sole power to vote or direct the vote:    33,931

    (ii)    Shared power to vote or direct the vote:     0

    (iii)   Sole power to dispose or to direct the disposition of:    33,931

    (iv)   Shared power to dispose or to direct the disposition of:     0

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date herof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   ☒

     

      

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security being Reported on by the Parent Holding Company.

     

    Not applicable.

     

     

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

    CUSIP No.  G1686P106

    13G Page 5 of 5 Pages    

     

     

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated:                    May 10, 2022

     

     
    KARPUS MANAGEMENT, INC.

     
           
    By:
    /s/ Jodi L.Hedberg  
        Name:  Jodi L. Hedberg  
        Title:    Chief Compliance Officer  
           

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $BHSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHSE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BHSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

    Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq G

    10/31/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

    SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

    9/21/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

    Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial

    5/17/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    SEC Filings

    View All

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:17:01 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:15:23 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/1/24 5:28:10 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BHSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/9/24 5:32:29 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)

    3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:01:21 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bull Horn Holdings Corp.

    SC 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/14/24 3:32:56 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bull Horn Holdings Corp. (Amendment)

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/6/23 4:25:12 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Bull Horn Holdings Corp.

    SC 13D - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/7/22 4:10:32 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care